IL145301A0 - 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders - Google Patents

1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders

Info

Publication number
IL145301A0
IL145301A0 IL14530100A IL14530100A IL145301A0 IL 145301 A0 IL145301 A0 IL 145301A0 IL 14530100 A IL14530100 A IL 14530100A IL 14530100 A IL14530100 A IL 14530100A IL 145301 A0 IL145301 A0 IL 145301A0
Authority
IL
Israel
Prior art keywords
arenesulfonyl
pyrrolidine
aryl
treatment
cns disorders
Prior art date
Application number
IL14530100A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL145301A0 publication Critical patent/IL145301A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
IL14530100A 1999-03-25 2000-03-18 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders IL145301A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25
PCT/EP2000/002431 WO2000058285A1 (en) 1999-03-25 2000-03-18 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
IL145301A0 true IL145301A0 (en) 2002-06-30

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14530100A IL145301A0 (en) 1999-03-25 2000-03-18 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders

Country Status (34)

Country Link
US (1) US6284785B1 (cs)
EP (1) EP1165510B1 (cs)
JP (1) JP3590589B2 (cs)
KR (1) KR100452648B1 (cs)
CN (1) CN1150165C (cs)
AR (1) AR028817A1 (cs)
AT (1) ATE305451T1 (cs)
AU (1) AU765212B2 (cs)
BR (1) BR0009278A (cs)
CA (1) CA2368418C (cs)
CO (1) CO5050296A1 (cs)
CZ (1) CZ20013402A3 (cs)
DE (1) DE60022867T2 (cs)
DK (1) DK1165510T3 (cs)
ES (1) ES2249249T3 (cs)
HK (1) HK1044944B (cs)
HR (1) HRP20010682A2 (cs)
HU (1) HUP0200284A3 (cs)
IL (1) IL145301A0 (cs)
JO (1) JO2274B1 (cs)
MA (1) MA26779A1 (cs)
MX (1) MXPA01009623A (cs)
MY (1) MY125295A (cs)
NO (1) NO319948B1 (cs)
NZ (1) NZ514037A (cs)
PE (1) PE20001583A1 (cs)
PL (1) PL204436B1 (cs)
RU (1) RU2248350C2 (cs)
SI (1) SI1165510T1 (cs)
TR (1) TR200102789T2 (cs)
TW (1) TW575561B (cs)
WO (1) WO2000058285A1 (cs)
YU (1) YU67601A (cs)
ZA (1) ZA200107689B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516904A (ja) 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
CA2555399A1 (en) * 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
US20060035884A1 (en) * 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
BRPI0615111B8 (pt) 2005-08-30 2021-05-25 Takeda Pharmaceuticals Co composto, composição farmacêutica, e, uso do composto
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2010024451A1 (en) 2008-08-27 2010-03-04 Takeda Pharmaceutical Company Limited Pyrrole compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) * 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK167393B1 (da) * 1985-12-30 1993-10-25 Roussel Uclaf 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
US5194439A (en) * 1990-04-06 1993-03-16 John Wyeth & Brother Limited N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes
NZ246295A (en) * 1991-12-18 1996-06-25 Schering Corp Imidazolylalkyl derivatives and pharmaceutical compositions; histamine h3 agonists and antagonists
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU3291500A (en) 2000-10-16
JO2274B1 (en) 2005-04-07
NO319948B1 (no) 2005-10-03
AR028817A1 (es) 2003-05-28
MXPA01009623A (es) 2002-05-06
AU765212B2 (en) 2003-09-11
SI1165510T1 (sl) 2005-12-31
JP2002540191A (ja) 2002-11-26
CO5050296A1 (es) 2001-06-27
ATE305451T1 (de) 2005-10-15
ES2249249T3 (es) 2006-04-01
BR0009278A (pt) 2001-12-26
TR200102789T2 (tr) 2002-04-22
CA2368418C (en) 2009-03-10
WO2000058285A1 (en) 2000-10-05
RU2248350C2 (ru) 2005-03-20
PE20001583A1 (es) 2001-01-15
YU67601A (sh) 2004-09-03
EP1165510A1 (en) 2002-01-02
PL204436B1 (pl) 2010-01-29
ZA200107689B (en) 2002-12-18
HK1044944B (zh) 2004-10-21
NZ514037A (en) 2004-01-30
TW575561B (en) 2004-02-11
KR100452648B1 (ko) 2004-10-12
NO20014617L (no) 2001-09-24
HRP20010682A2 (en) 2002-10-31
JP3590589B2 (ja) 2004-11-17
MY125295A (en) 2006-07-31
HUP0200284A3 (en) 2003-04-28
HK1044944A1 (en) 2002-11-08
CA2368418A1 (en) 2000-10-05
CN1345311A (zh) 2002-04-17
HUP0200284A2 (en) 2002-06-29
KR20010108403A (ko) 2001-12-07
MA26779A1 (fr) 2004-12-20
EP1165510B1 (en) 2005-09-28
DE60022867T2 (de) 2006-06-22
US6284785B1 (en) 2001-09-04
CN1150165C (zh) 2004-05-19
NO20014617D0 (no) 2001-09-24
CZ20013402A3 (cs) 2002-03-13
PL350679A1 (en) 2003-01-27
DK1165510T3 (da) 2006-02-06
DE60022867D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
IL149530A0 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
SI1231920T1 (sl) Uporaba epinastina za zdravljenje alergijskega renitisa/konjuktivitisa
AU6910600A (en) Methods for the treatment of mental disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
IL154051A0 (en) 4-,5-,6-, and 7-indole derivatives useful for the treatment of cns disorders
AU7388101A (en) Indole derivatives useful for the treatment of cns disorders
HUP0104701A3 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders and medicaments containing the compounds
EP1181308A4 (en) METHODS OF TREATING NEURONAL DEMENTIA ASSOCIATED WITH ATROPHY
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
AU8173801A (en) Indole derivatives useful for the treatment of cns disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
PL351554A1 (en) Osanetant in the treatment of mood disorders
IL153254A0 (en) Indole derivatives useful for the treatment of cns disorders
AU2080201A (en) Treatment of addiction disorders
SG82014A1 (en) The use of aryl-cyclohexylamine derivatives against cns disorders
AU6007900A (en) Azetidine carboxamide derivatives for the treatment of cns disorders
IL139018A0 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
IL153351A0 (en) Indole derivatives useful for the treatment of cns disorders
IL153234A0 (en) Indole derivatives useful for the treatment of cns disorders